Nkarta (NASDAQ:NKTX) Price Target Lowered to $14.00 at Stifel Nicolaus

Nkarta (NASDAQ:NKTX) had its target price reduced by investment analysts at Stifel Nicolaus from $15.00 to $14.00 in a research note issued on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock.

Several other analysts also recently issued reports on NKTX. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price target on shares of Nkarta in a report on Thursday. Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 target price on shares of Nkarta in a research note on Thursday. Six equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $14.86.

Nkarta Trading Down 4.2 %

Shares of Nkarta stock opened at $1.37 on Thursday. The stock has a market cap of $96.68 million, a PE ratio of -0.73 and a beta of 0.90. The company has a 50-day moving average of $2.01 and a two-hundred day moving average of $2.90. Nkarta has a 12-month low of $1.31 and a 12-month high of $11.84.

Nkarta (NASDAQ:NKTX) last posted its earnings results on Wednesday, March 26th. The company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.06. On average, sell-side analysts forecast that Nkarta will post -1.7 EPS for the current fiscal year.

Insider Buying and Selling

In other Nkarta news, CEO Paul J. Hastings sold 17,378 shares of the business’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $2.20, for a total transaction of $38,231.60. Following the completion of the sale, the chief executive officer now owns 319,859 shares of the company’s stock, valued at approximately $703,689.80. The trade was a 5.15 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 8.70% of the company’s stock.

Institutional Investors Weigh In On Nkarta

Several large investors have recently made changes to their positions in NKTX. Wasatch Advisors LP boosted its position in Nkarta by 31.7% during the 3rd quarter. Wasatch Advisors LP now owns 1,834,680 shares of the company’s stock worth $8,293,000 after purchasing an additional 442,125 shares during the period. Geode Capital Management LLC grew its stake in shares of Nkarta by 3.0% in the third quarter. Geode Capital Management LLC now owns 1,171,026 shares of the company’s stock valued at $5,294,000 after buying an additional 33,927 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Nkarta by 252.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,063,362 shares of the company’s stock valued at $4,806,000 after buying an additional 761,349 shares during the period. Franklin Resources Inc. acquired a new position in Nkarta during the 3rd quarter worth approximately $151,000. Finally, FMR LLC raised its stake in shares of Nkarta by 97.1% during the third quarter. FMR LLC now owns 133,149 shares of the company’s stock valued at $602,000 after purchasing an additional 65,600 shares during the period. Institutional investors and hedge funds own 80.54% of the company’s stock.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.